Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  OpGen, Inc.    OPGN


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

OpGen : Corporate Presentation (PDF)

share with twitter share with LinkedIn share with facebook
09/14/2020 | 03:10pm EDT


Corporate Overview

September 2020

Forward looking statements disclaimer

This presentation contains forward-looking statements that are subject to many risks and uncertainties. These statements, among other things, relate to our business strategy, goals and expectations concerning our products, future operations, prospects, plans and objectives of management. The words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will" and similar terms and phrases are used to identify forward-looking statements in this presentation. These statements and other statements regarding our future plans constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1955. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond OpGen's control, and that may cause results to differ materially from expectations.

Factors that could cause results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and service offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the realization of expected synergies from our business combination transaction with Curetis GmbH, the successful integration of our company with the operations and business of Curetis GmbH and its subsidiaries and the implementation of the combined company's strategic and business goals and objectives, the impact of COVID- 19 on our operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the ability to comply with the complexities of operating a global business, the success of our commercialization efforts, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this presentation and speak only as of the date of this presentation. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

©2020 OpGen, Inc.


OpGen and its group companies:

Striving to innovate molecular microbiology





Rapid Pathogen

Broad Pathogen &

AI-Powered AMR


Detection For Life

Antimicrobial Resistance

Prediction &


Threatening Infections

(AMR) Marker Coverage


©2020 OpGen, Inc.


Combined company's portfolio:

Synergistic products & capabilities

Unyvero Platform

Acuitas Tests &

Global Commercial

Ares Genetics NGS &

& Syndromic Tests

Acuitas Lighthouse



Unyvero FDA-cleared platform for lower respiratory tract infection (LRT & LRT BAL) as well as 5 CE IVD tests; Unyvero A30 RQ platform

in development

Acuitas AMR Gene Panel tests in clinical trials (Urine) and pending FDA clearance (isolates) to improve antibiotic decision making; Lighthouse knowledge base deployed for public health use

Direct sales in U.S., European and China distribution with partners; 18 distributors covering

43 countries; CoV-2 test kit distribution in EMEA

Ares Technology for AI-powered AMR prediction combining ARESdb with NGS; Strategic partnerships with globally leading IVD & pharma companies

©2020 OpGen, Inc.


This is an excerpt of the original content. To continue reading it, access the original document here.


OpGen Inc. published this content on 14 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 September 2020 19:09:05 UTC

share with twitter share with LinkedIn share with facebook
All news about OPGEN, INC.
10/15OPGEN INC : Results of Operations and Financial Condition (form 8-K)
10/15OPGEN : Provides Business and Pipeline Update and Announces Preliminary Unaudite..
10/15OpGen Provides Business and Pipeline Update and Announces Preliminary Unaudit..
10/13OPGEN : Issues Formal Response to FDA's Requests for Additional Information and ..
10/13OpGen Issues Formal Response to FDA's Requests for Additional Information and..
10/06OPGEN : Corporate Presentation (PDF)
10/05OpGen Group Company Ares Genetics Wins Austrian Digitization Award for ares-g..
10/05OPGEN : Ares Genetics Wins Austrian Digitization Award for ares-genetics.cloud
10/02OPGEN INC : Change in Directors or Principal Officers, Submission of Matters to ..
09/30OPGEN : Announces Award of German Government Grant Funding to its Subsidiary Cur..
More news
Financials (USD)
Sales 2020 4,29 M - -
Net income 2020 -24,7 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,53x
Yield 2020 -
Capitalization 48,7 M 48,7 M -
Capi. / Sales 2020 11,3x
Capi. / Sales 2021 4,38x
Nbr of Employees 39
Free-Float 99,9%
Duration : Period :
OpGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPGEN, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 3
Average target price 5,00 $
Last Close Price 2,47 $
Spread / Highest target 102%
Spread / Average Target 102%
Spread / Lowest Target 102%
EPS Revisions
Oliver Schacht Chief Executive Officer & Director
Bill E. Rhodes Non-Executive Chairman
Johannes Bacher Chief Operating Officer
Timothy C. Dec CFO, Secretary & Chief Accounting Officer
Vadim Sapiro Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
OPGEN, INC.118.58%49
LONZA GROUP AG62.80%47 152
SEAGEN INC.72.54%34 263
CELLTRION, INC.31.49%28 160
MODERNA, INC.260.58%27 830